

1 **Variations in Risk Factors across Different Periods of Stroke Recurrence**

2

3 Sang-Hun Lee, MD, PhD; Jin-Man Jung, MD, PhD; Jae-Chan Ryu, MD; Moon-Ho Park, MD,

4 PhD

5 Department of Neurology, Korea University Ansan Hospital, Korea University College of

6 Medicine, Ansan, Republic of Korea

7 **Correspondence to:**

8 Moon-Ho Park, MD, PhD

9 Department of Neurology, Korea University Ansan Hospital, Korea University College of

10 Medicine, Gojan 1-Dong, Danwon-Gu, Ansan-si, Gyeonggi-do 152-703, Republic of Korea

11 Tel: +82-31-412-5150, FAX: +82-31-412-5154

12 E-mail: parkmuno@korea.ac.kr

13 **Short title:** Stroke recurrence and risk factors

14 **Number of characters in the title:** 72

15 **Number of words in the manuscript:** 3004

16 **Number of figures:** 3

17 **Number of table:** 1

18 **Number of supplementary table:** 1

19

20

21 **Abstract**

22 **Background and Purpose:** Accurately discerning periods of heightened risk of stroke
23 recurrence and managing modifiable risk factors are essential for minimizing overall
24 recurrence risk. This study identified differences in the timing of stroke recurrence based on
25 risk factors and patient characteristics to develop strategies for reducing recurrence in clinical
26 practice.

27 **Methods:** We retrospectively selected patients with ischemic stroke or transient ischemic
28 attack at the Korea University Ansan Hospital Stroke Center between March 2014 and
29 December 2021 using the prospective institutional database of the Korea University Stroke
30 Registry. We collected demographic, clinical, and stroke data and categorized participants by
31 recurrence timing (early within 3 months or late after 3 months). Using multinomial logistic
32 regression analysis, we examined variables associated with early and late recurrent strokes.

33 **Results:** The analysis included 3,646 patients, of whom 255 experienced a recurrent stroke
34 and 3,391 experienced their first stroke. Multinomial logistic regression analysis revealed
35 significant associations between early recurrent stroke and diabetes mellitus (OR 1.98, 95%
36 CI 1.25–3.15), other determined etiologies in TOAST classification (OR 3.00, 95% CI 1.37–
37 6.61), and white matter changes (OR 1.97, 95% CI 1.17–3.33). Late recurrent stroke showed
38 a significant correlation with transient ischemic attack (TIA) (OR 2.95, 95% CI 1.52–5.71)
39 and cerebral microbleeds (OR 2.22, 95% CI 1.32–3.75).

40 **Conclusion:** Our study emphasizes substantial differences in factors contributing to stroke
41 recurrence based on timing. Managing the risk of recurrence in clinical practice necessitates
42 accurate identification of heightened risk periods and rigorous control of modifiable risk
43 factors.

44 **Keywords: stroke recurrence, early recurrent stroke, late recurrent stroke**

45 **Introduction**

46 Stroke is a disabling disease that causes high mortality rates and a significant decline in
47 quality of life worldwide (1-3). Stroke exhibits a frequent recurrence compared to other
48 diseases (4,5). Recurrent stroke causes more serious neurological damage, is more difficult to
49 treat, and carries a higher risk of death, readmission, and long-term disability than the first
50 stroke. Therefore, secondary prevention after the first stroke is critical to reducing stroke
51 recurrence (6).

52 Understanding recurrent stroke is important. Previous studies have investigated
53 important variables for stroke recurrence, including age, diabetes, smoking, arterial
54 hypertension, hyperlipidemia, peripheral arterial disease, hypercoagulable states, depression,
55 and the National Institutes of Health Stroke Scale (NIHSS) score status (7-10). The
56 cumulative incidence of stroke recurrence in the first 5 years is 16–30% (11-13). However,
57 the stroke recurrence rate varies significantly over time, particularly after the initial stroke.
58 The timing of recurrence shows significant heterogeneity depending on the risk factors (3).
59 The risk of recurrence ranged from 3.54 to 24.5% in the first year after the first stroke (14,15);
60 the 2-year recurrence rate was approximately 30% (6); and in the following 5 years, it was in
61 the range of 9.4% to 22.90% (16,17).

62 Precision in identifying the heightened risk of stroke recurrence and managing
63 modifiable risk factors is crucial for minimizing the overall recurrence risk. The existing
64 literature has overlooked early recurrence in the subacute phase, which occurs within 3
65 months after cerebral infarction. Consequently, our study aimed to address this research gap
66 by identifying the risk factors and characteristics associated with early recurrence,
67 particularly within the initial 3-month period. These findings provide valuable insights for
68 clinical practice, aiding in the reduction of early recurrence rates.

69

70

71 **Methods**

72 Participants

73 This is a prospective institutional database from the Korea University Stroke Registry.
74 The design of the database has been described in detail previously (18). Briefly, we
75 retrospectively selected consecutive patients with ischemic stroke or transient ischemic attack
76 (TIA) (diagnosed by a neurologist within 30 days of the event) who were admitted to the
77 stroke center of Korea University Ansan Hospital between March 2014 and December 2021
78 due to neurological problems. Patients with hemorrhagic strokes were excluded from the
79 study. (Figure 1) Stroke was defined as focal clinical signs of central nervous system
80 dysfunction of vascular origin that lasted for at least 24 h according to the World Health
81 Organization (Geneva) criteria. TIA was defined as losing cerebral or ocular function for less
82 than 24 h. The recurrence of cerebral infarction was determined by neurological symptoms
83 and ischemic changes detected on imaging tests.

84 Information on demographics, clinical evaluations, neurological examinations, stroke
85 characteristics, and outcomes was obtained. The diagnosis required brain computed
86 tomography (CT) and/or magnetic resonance imaging (MRI) to exclude hemorrhage and
87 other causes of symptoms. Each patient required at least one vascular imaging scan, including
88 conventional angiography, arterial imaging using MR angiography, CT angiography, or
89 duplex ultrasound imaging. Standard systemic investigations were performed for every
90 patient, including routine laboratory tests, chest radiography, and 12-lead electrocardiography.
91 Routine laboratory tests included a complete blood count, electrolyte, glucose, renal function,
92 liver function, lipid profile, and homocysteine levels. Transcranial Doppler, carotid duplex
93 sonography, transthoracic echocardiography, transesophageal echocardiography, and 24-h
94 Holter electrocardiography monitoring were performed in selected patients. This study was
95 approved by the Institutional Review Board of Korea University Ansan Hospital (approval no.

96 AS0213). Informed consent was not required owing to the retrospective design of the study.

97

98 *Clinical and Laboratory Assessment*

99 For demographics and comorbidities, age at admission was categorized into three
100 groups (<60, 60–74, and ≥ 75 years). Body mass index (BMI) was calculated as weight in
101 kilograms divided by height in meters squared (kg/m^2) and was categorized into four groups
102 (underweight, <18.5; normal weight, 18.5–22.9; overweight, 23.0–24.9; obese, ≥ 25.0) by
103 modified previous criteria (19). The weight and height required for BMI measurements were
104 measured within 24 h of admission. The smoking status was classified as current smoker or
105 nonsmoker. Hypertension was defined as a systolic blood pressure of at least 140 mmHg, a
106 diastolic blood pressure of at least 90 mmHg, or the presence of hypertension when patients
107 were previously diagnosed or were receiving antihypertensive medication. Diabetes mellitus
108 was defined as a fasting serum glucose level of ≥ 126 mg/dL, a non-fasting serum glucose
109 level of ≥ 200 mg/dL, a hemoglobin A1c level of $\geq 6.5\%$, or a history of insulin therapy and/or
110 oral hypoglycemic drugs. Dyslipidemia was defined as a total cholesterol level of ≥ 200
111 mg/dL. Blood samples were obtained from all participants after at least 8 h of fasting on the
112 morning of admission. Stroke is associated with abnormal biochemical parameters, including
113 anemia (20), leukocytosis (21), elevated high-sensitivity C-reactive protein (CRP) levels (21),
114 high homocysteine levels (22), and reduced kidney function (23). In this study, these
115 biochemical cut-off points were used to define and categorize abnormal levels: anemia was
116 defined as hemoglobin <12 g/dL in females and <13 g/dL in males; leukocytosis was defined
117 as a white blood count of $>12,000/\mu\text{L}$; hyperhomocysteinemia ≥ 15 $\mu\text{mol}/\text{L}$; CRP elevation >2
118 mg/L; and abnormal kidney function as estimated glomerular filtration rate <60 mL/min per
119 1.73 m^2 .
120 Congestive heart failure was defined as a reduced left ventricular ejection fraction (<50%).

121 Atrial fibrillation (AF) was defined as persistent atrial arrhythmia with irregular R-R intervals
122 and no clear repetitive P waves and was diagnosed with an electrocardiogram, 24-h Holter, or
123 continuous electrocardiogram monitoring during hospitalization.

124 White matter changes (WMCs) in the hemisphere contralateral to the area affected by the
125 acute stroke were assessed using the proposed visual rating scale (24,25). If the WMCs were
126 higher on one side, the rating was based on the less involved or uninvolved side with the
127 assumption of symmetry. In this study, the WMCs rating was modified using a dichotomous
128 method (WMCs, grade 3 vs. no WMCS, grades 1–2). Cerebral microbleeds (CMBs) were
129 assessed as rounded or ovoid hypointense lesions on a T2-GRE-weighted sequence of MRI
130 (26). CMBs measured 10 mm or less in diameter and were surrounded by brain parenchyma
131 over at least half the circumference of the lesion. The severity of neurological deficits at
132 admission was rated using the National Institutes of Health Stroke Scale (NIHSS) score (27)
133 on the day of admission, defined as poor initial NIHSS (NIHSS score ≥ 5), which was
134 evaluated by the certified neurologists who were blind to this study.

135 For subtypes of stroke, ischemic stroke was classified according to the Trial of Org
136 10172 in the Acute Stroke Treatment (TOAST) classification system (28): large artery disease
137 (LAD), cardioembolism (CE), small vessel occlusion (SVO), stroke of other determined
138 etiology (OD), and stroke of undetermined etiology (UD). The UD category included three
139 heterogeneous groups: “two or more causes,” “negative evaluation,” and “incomplete
140 evaluation.” Recurrent stroke was defined as a new neurological deficit or deterioration of the
141 previous deficit and fit the definitions for ischemic stroke, or TIA. Recurrent stroke was
142 classified according to the recurrent interval as early recurrent stroke (≤ 3 months) or late
143 recurrent stroke (> 3 months). The extent of the diagnostic workup, stroke, and TIA were
144 determined primarily by the stroke neurologists in charge of the patients, and the types of
145 stroke and TIA were confirmed at a monthly stroke registry meeting.

146

147 Statistical Analysis

148 All participants were categorized according to stroke recurrence (recurrent stroke
149 group and first-ever stroke group), and the recurrent stroke group was further subcategorized
150 into early and late recurrent stroke groups. Categorical variables are described in terms of
151 frequencies and percentages. Differences in characteristics among groups were analyzed
152 using Pearson's chi-squared (χ^2) test or Fisher's exact test, as applicable. A pairwise z -test
153 with the Bonferroni correction was used to determine the significance of the contribution of
154 each subgroup of variables.

155 To identify potential predictors of recurrent stroke, we selected variables with $P < 0.2$
156 in a bivariable analysis. We used a modified Nightingale-Rose diagram to show the
157 distribution of potential predictors of recurrent stroke. These potential variables of recurrent
158 stroke were used to generate a predictive model for each recurrent stroke by multivariable
159 binary and multinomial logistic regression models using bootstrapping methods with a
160 statistically significant association at $P < 0.05$ compared to those of first-ever stroke.
161 Goodness-to-fit and pseudo-R square statistics were used to evaluate the model fit and
162 predictive strength. The final models were used to calculate the adjusted odds ratios (ORs)
163 and 95% confidence intervals (CIs).

164 Statistical significance was declared when the two-tailed P -value was < 0.05 .
165 Statistical analyses were performed using R version 4.2.1 software (R Foundation for
166 Statistical Computing, Vienna, Austria) and SPSS (version 20.0; IBM SPSS, Chicago, IL,
167 USA).

168

169 **Results**

170 Between March 2014 and December 2021, 4,508 individuals with ischemic stroke or

171 transient ischemic attack (TIA) were admitted to the Stroke Center at Korea University Ansan
172 Hospital. Of these, 862 patients were excluded from the final analysis, comprising 709
173 patients who refused the omission of tests for the stroke registry and 153 patients who were
174 lost during the evaluation period for stroke recurrence. Consequently, the final analysis
175 included 3,646 patients, of whom 255 experienced recurrent strokes and 3,391 had their first
176 stroke. (Figure 1)

177

178 Differential Clinical Characteristics in Recurrent Stroke Versus First-Ever

179 Table 1 outlines the demographic and clinical features of the participants according
180 to the occurrence of stroke recurrence. The recurrent stroke patient group had a significantly
181 higher proportion of men than the first-ever stroke group (71.4% vs. 60.4%, $p = 0.001$).
182 Variations in BMI across categories, such as normal, underweight, overweight, and obese,
183 showed that patients with the underweight category (BMI 18.5–22.9) showed a significantly
184 higher rate of recurrent stroke (9.1% vs. 4.4%, $p = 0.005$).

185 Concerning stroke risk factors, higher recurrence rates were observed in individuals
186 with hypertension, diabetes mellitus, and congestive heart failure. Stratifying participants
187 based on stroke subtype according to the TOAST (Trial of Org. 10172 in Acute Stroke
188 Treatment) classification revealed a significantly lower recurrence rate in cases of small
189 vessel occlusion (SVO) (14.9% vs. 24.8%, $p = 0.005$).

190 Laboratory findings indicated a higher prevalence of anemia, elevated CRP levels
191 exceeding 2 mg/dL, and a low estimated glomerular filtration rate (eGFR) in recurrent
192 cerebral infarctions. In terms of radiological findings, white matter changes and cerebral
193 microbleeds were associated with recurrent strokes.

194

195 Differences in Clinical Characteristics among Early Recurrent Stroke, Rate Recurrent Stroke,

196 and First-Ever Stroke

197 Figure 2. summarizes the analysis of the differences between the initial recurrent
198 stroke, recurrent stroke rate, and first stroke using a diagram. For variables such as male sex,
199 diabetes mellitus, TOAST classification, anemia, and cerebral microbleeds, patients with
200 early and late recurrent stroke showed similar patterns of significant differences when
201 compared with patients with first-ever stroke.

202 Regarding BMI ($p = 0.002$), congestive heart failure ($p = 0.024$), leukocytosis ($p =$
203 0.029), and white matter changes ($p < 0.001$), significant differences were observed in
204 comparison to first-ever stroke patients only in the early recurrent stroke group. However,
205 regarding dyslipidemia ($p = 0.047$), significant differences in patients with first-ever stroke
206 were observed only in the late recurrent stroke group.

207 A comparison of early and late recurrent strokes showed significant differences in
208 TOAST classification and CRP levels. This is expressed in detail in Supplementary Table 1.

209

210 Multivariable Logistic Regression Analysis of Predictive Factors for Early and Late

211 Recurrent Stroke

212 A multinomial logistic regression analysis was used to analyze the early and late
213 recurrent stroke variables. (Figure 3) For overall recurrent stroke, male sex (OR 2.05, 95% CI
214 1.45–2.88), hypertension (OR 1.54, 95% CI 1.06–2.22), diabetes mellitus (OR 1.59, 95% CI
215 1.15–2.18), other determined etiologies in TOAST classification (OR 1.98, 95% CI 1.04–
216 3.78), TIA (OR 2.01, 95% CI 1.18–3.43), anemia (OR 3.96, 95% CI 2.81–5.57), white matter
217 changes (OR 1.62, 95% CI 1.08–2.44), and cerebral microbleeds (OR 1.88, 95% CI 1.29–
218 2.72) showed significant results.

219 In the context of early recurrent stroke, significant associations were observed for
220 diabetes mellitus (OR 1.98, 95% CI 1.25–3.15), other determined etiology in TOAST

221 classification (OR 3.00, 95% CI 1.37–6.61), and white matter changes (OR 1.97, 95% CI
222 1.17–3.33). Conversely, in the case of late recurrent stroke, a significant correlation was
223 noted with the transient ischemic attack (TIA) (OR 2.95, 95% CI 1.52–5.71) and cerebral
224 microbleeds (OR 2.22, 95% CI 1.32–3.75). Additionally, for both early and late recurrent
225 stroke, significant associations were observed with male sex (OR 1.98, 95% CI 1.25–3.15;
226 OR 2.14, 95% CI 1.32–3.48, respectively) and anemia (OR 4.53, 95% CI 2.84–7.20; OR 3.40,
227 95% CI 2.10–5.51, respectively).

228

229 **Discussion**

230 In this study, we focused on understanding the factors influencing stroke recurrence and
231 distinguishing patients experiencing a recurrent stroke from those who experienced a first-
232 ever stroke. Given the dynamic nature of stroke recurrence, we anticipated variations in
233 causative factors over time. Consequently, we categorized our analysis into early and late
234 periods based on a 3-month timeframe.

235 Our findings indicate that certain factors are closely associated with stroke
236 recurrence within the first 3 months. Patients with diabetes mellitus, other determined
237 etiologies according to the TOAST classification, and white matter changes were particularly
238 prone to early recurrence. By contrast, individuals with TIA and cerebral microbleeds
239 exhibited a higher likelihood of delayed relapse. Regardless of the timing, male sex and
240 anemia were identified as consistent risk factors for recurrence.

241 Our investigation aligns with previous studies that explored stroke recurrence. Lee et
242 al. discovered that the risk of 1-year stroke recurrence was significantly elevated in men,
243 older adults, and those with a history of ischemic stroke (29). A meta-analysis by Zheng et al.
244 suggested that hypertension, diabetes, atrial fibrillation, and coronary heart disease are
245 associated with a heightened risk of stroke recurrence (30). In a study by Hillen et al.,

246 diabetes and atrial fibrillation emerged as significant contributors to outcomes in the first year
247 after the index stroke (31). These risk factors are associated with stroke recurrence, with
248 significant differences. Reviewing multiple prior studies, the most firmly established risk
249 factors linked to stroke recurrence were diabetes and atrial fibrillation (32-35). This is
250 consistent with the current research showing that diabetes is a crucial factor. Regarding atrial
251 fibrillation, our study suggests a tendency for a higher prevalence in patients experiencing
252 recurrent cerebral infarction. However, the results no longer reached statistical significance.
253 This observation could be attributed to the widespread clinical use of NOACs and the
254 heightened early atrial fibrillation detection rate facilitated by tools such as injectable cardiac
255 monitors and long-term Continuous Ambulatory ECG Monitors.

256 Previous research results on hypertension were more heterogeneous, and several
257 studies reported that hypertension was associated with the highest risk of stroke recurrence.
258 However, few studies reported a significant association with stroke recurrence, which may be
259 related to different criteria and methods for measuring hypertension and issues with
260 antihypertensive management (9,31,32,35,36). Although this study demonstrated a
261 correlation with overall stroke recurrence, no significant correlation was observed with early
262 recurrent stroke.

263 In our study, a high initial recurrence rate was observed in the category of "other
264 determined etiology" in the TOAST classification, consistent with findings from previous
265 research. Specifically, within this classification, the majority of patients exhibited dissection,
266 Moyamoya disease, and cancer-related coagulopathy, which is consistent with past studies
267 that have identified these conditions as being associated with elevated recurrence rates. For
268 instance, Christian Weimar et al. highlighted the heightened risk of early recurrent stroke
269 following acute ischemic stroke, or TIA, attributed to carotid artery dissection (37). Moreover,
270 a study by Chiu et al. indicated that Moyamoya disease entails a high risk of stroke

271 recurrence, with an 18% recurrence rate within the first year after diagnosis, decreasing to
272 approximately 5% over the subsequent 5 years (38). This trend may be influenced by the
273 gradual development of angiogenesis and collaterals following the initial cerebral infarction.
274 The recurrence rate was higher in patients with cancer-related strokes than in patients with
275 inactive cancer or controls. The estimated one-year stroke recurrence rate in patients with
276 cancer and embolic stroke of undetermined source (ESUS) ranges from 14% to 29%, which
277 is approximately three times higher than that in ESUS patients without cancer (35). White
278 matter changes (WMCs) indicate stroke recurrence up to 5 years after the first ischemic
279 stroke. This shows that white matter change (WMC) can be considered an SVD marker that
280 summarizes the impact of several classical risk factors on small-vessel brain networks (39).
281 We observed that WMC had a particularly strong impact on early recurrent strokes.
282 Conversely, the association between TIA and late recurrent stroke can be attributed to the
283 possibility that symptoms are not observed for an extended duration during the treatment
284 process. The risk factors are effectively managed, and clinicians may opt to discontinue
285 antithrombotic drugs in clinical practice. Considerably, the risk of recurrence in these cases
286 being detected after a long period of time is higher compared to patients with cerebral
287 infarction who consistently adhere to antithrombotic therapy.

288 Our study has several limitations. First, this was a single-hospital investigation.
289 Inherent in utilizing clinical registry data is a potential bias in patient selection, recording
290 practices, data completeness, and outcome assessment. Therefore, generalizing the findings
291 of this study may be challenging. To bolster the robustness of these results, it is imperative to
292 validate them through prospective multicenter studies with larger sample sizes. Second, a
293 challenge in examining stroke recurrence is the difficulty of identifying such recurrences,
294 particularly if they manifest immediately after the index stroke. Detecting new neurological
295 signs in unconscious, paralyzed, or bedridden patients with a Modified Rankin Scale (mRS)

296 score of 4 or higher is markedly more challenging than in individuals who have recovered.
297 Third, while we categorized stroke recurrence into early (within three months) and late
298 (beyond three months) groups, a more nuanced classification of the late recurrence group
299 could have yielded more detailed insights. Lastly, during the initial 3 months, the loss of
300 follow-up was minimal. However, beyond this period, patients exhibited increased loss of
301 follow-up, potentially introducing bias to our findings.

302 In conclusion, our study underscores the substantial differences in the causative
303 factors of stroke recurrence, contingent on the timing of recurrence. Effectively mitigating the
304 risk of recurrence in clinical practice necessitates accurately identifying periods when the risk
305 of stroke recurrence is heightened, coupled with stringent control of modifiable risk factors.

306

307 **Acknowledgments:** None.

308 **Sources of funding:** This work was supported by the National Research Foundation of Korea
309 (NRF) grant funded by the Korea Government (Ministry of Science and ICT) (RS-2023-
310 00246890).

311 **Conflict of Interest**

312 The authors have no financial conflicts of interest.

313 **Author contributions:**

314 Dr. SH Lee contributed to the study conception and design, data analysis, acquisition of
315 clinical and imaging data, statistical analysis, and manuscript drafting and revision.

316 Dr. MH Park contributed to the study conception and design, analysis, and interpretation of
317 the imaging and clinical data, manuscript drafting and revision, and study supervision.

318 Dr. JM Jung contributed to the data analysis and manuscript revision.

319 Dr. JC Ryu contributed to the study conception and data statistical analysis.

320

321

322 **References**

323 1. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. *Circulation Research*.
324 2017;120:439–448.

325 2. Mahesh PKB, Gunathunga MW, Jayasinghe S, Arnold SM, Liyanage SN. Factors
326 influencing pre-stroke and post-stroke quality of life among stroke survivors in a
327 lower middle-income country. *Neurological Sciences*. 2018;39:287–295.

328 3. Lin B, Zhang Z, Mei Y, Wang C, Xu H, Liu L, Wang W. Cumulative risk of stroke
329 recurrence over the last 10 years: A systematic review and meta-analysis.
330 *Neurological Sciences*. 2021;42:61–71.

331 4. Han J, Mao W, Ni J, Wu Y, Liu J, Bai L, Shi M, Tu J, Ning X, Wang J. Rate and
332 determinants of recurrence at 1 year and 5 years after stroke in a low-income
333 population in rural china. *Frontiers in Neurology*. 2020;11:2.

334 5. Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in china: huge burden,
335 significant workload, and a national priority. *Stroke*. 2011;42:3651-3654.

336 6. Zhuo Y, Wu J, Qu Y, Yu H, Huang X, Zee B, Lee J, Yang Z. Clinical risk factors
337 associated with recurrence of ischemic stroke within two years: A cohort study.
338 *Medicine (Baltimore)*. 2020;99:e20830.

339 7. Modrego PJ, Mainar R, Turull L. Recurrence and survival after first-ever stroke in the
340 area of bajo Aragon, Spain. A prospective cohort study. *Journal of the Neurological
341 Sciences*. 2004;224:49–55.

342 8. Lee AH, Somerford PJ, Yau KK. Risk factors for ischaemic stroke recurrence after

- 343 hospitalisation. *Medical Journal of Australia*. 2004;181:244–246.
- 344 9. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence
345 after hospitalized cerebral infarction in an urban community: the northern manhattan
346 stroke study. *Neurology*. 1994;44:626–634.
- 347 10. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence:
348 predictors, severity, and prognosis. The Copenhagen stroke study. *Neurology*.
349 1997;48:891–895.
- 350 11. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU.
351 Epidemiology of ischemic stroke subtypes according to toast criteria: incidence,
352 recurrence, and long-term survival in ischemic stroke subtypes: A population-based
353 study. *Stroke*. 2001;32:2735–2740.
- 354 12. Mohan KM, Crichton SL, Grieve AP, Rudd AG, Wolfe CD, Heuschmann PU.
355 Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke:
356 the south london stroke register. *Journal of Neurology, Neurosurgery, and Psychiatry*.
357 2009;80:1012–1018.
- 358 13. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve
359 AP. Risk and cumulative risk of stroke recurrence: A systematic review and meta-
360 analysis. *Stroke*. 2011;42:1489–1494.
- 361 14. Pu YH, Zou XY, Wang YL, Pan YS, Xiang XL, Soo AX, Leung HK, Zhao XQ, Wang
362 CX, Wong JX, et al. Difference of one year death and stroke recurrence in ischemic
363 stroke patients with anterior and posterior circulation intracranial atherosclerosis.
364 *Zhonghua Yi Xue Za Zhi*. 2018;98:502–507.
- 365 15. Kono Y, Yamada S, Kamisaka K, Araki A, Fujioka Y, Yasui K, Hasegawa Y, Koike Y.
366 Recurrence risk after noncardioembolic mild ischemic stroke in a Japanese population.
367 *Cerebrovascular Diseases*. 2011;31:365–372.

- 368 16. Putaala J, Haapaniemi E, Metso AJ, Metso TM, Artto V, Kaste M, Tatlisumak T.
369 Recurrent ischemic events in young adults after first-ever ischemic stroke. *Annals of*
370 *Neurology*. 2010;68:661–671.
- 371 17. Kumral E, Güllüoğlu H, Alakbarova N, Karaman B, Deveci EE, Bayramov A,
372 Evyapan D, Gökçay F, Orman M. Association of leukoaraiosis with stroke recurrence
373 within 5 years after initial stroke. *Journal of Stroke and Cerebrovascular Diseases*.
374 2015;24:573–582.
- 375 18. Lee SH, Jung JM, Park MH. Obesity paradox and stroke outcomes according to stroke
376 subtype: A propensity score-matched analysis. *International Journal of Obesity*.
377 2023;47:669–676.
- 378 19. World Health Organization. Regional office for the western pacific. The asia-pacific
379 perspective: redefining obesity and its treatment. Sydney: Health Communications
380 Australia; 2000.
- 381 20. Li Z, Zhou T, Li Y, Chen P, Chen L. Anemia increases the mortality risk in patients
382 with stroke: A meta-analysis of cohort studies. *Scientific Reports*. 2016;6:26636.
- 383 21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M,
384 Fagl YY, Fortmann SP, Hong Y, Myers GL, et al. Markers of inflammation and
385 cardiovascular disease: application to clinical and public health practice: A statement
386 for healthcare professionals from the Centers for Disease Control and Prevention and
387 the American Heart Association. *Circulation*. 2003;107:499–511.
- 388 22. Jung JM, Kwon DY, Han C, Jo I, Jo SA, Park MH. Increased carotid intima-media
389 thickness and plasma homocysteine levels predict cardiovascular and all-cause death:
390 A population-based cohort study. *European Neurology*. 2013;70:1–5.
- 391 23. Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, Wong CX, Sarnak M,
392 Cheung M, Herzog CA, et al. Chronic kidney disease and cerebrovascular disease:

- 393 consensus and guidance from a kdigo controversies conference. *Stroke*. 2021;52:e328-
394 e346.
- 395 24. Park JH, Heo SH, Lee MH, Kwon HS, Kwon SU, Lee JS, PICASSO investigators.
396 White matter hyperintensities and recurrent stroke risk in patients with stroke with
397 small-vessel disease. *European Journal of Neurology*. 2019;26:911–918.
- 398 25. Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H,
399 Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, et al. Impact of age-related cerebral
400 white matter changes on the transition to disability -- the Ladis study: rationale,
401 design and methodology. *Neuroepidemiology*. 2005;24:51–62.
- 402 26. Romero JR, Beiser A, Himali JJ, Shoamanesh A, DeCarli C, Seshadri S. Cerebral
403 microbleeds and risk of incident dementia: the Framingham heart study. *Neurobiology
404 of Aging*. 2017;54:94–99.
- 405 27. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J,
406 Marler J. Improved reliability of the nih stroke scale using video training. NINDS tpa
407 stroke study group. *Stroke*. 1994;25:2220–2226.
- 408 28. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE.
409 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter
410 clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. *Stroke*.
411 1993;24:35–41.
- 412 29. Lee JD, Hu YH, Lee M, Huang YC, Kuo YW, Lee TH. High risk of one-year stroke
413 recurrence in patients with younger age and prior history of ischemic stroke. *Current
414 Neurovascular Research*. 2019;16:250–257.
- 415 30. Zheng S, Yao B. Impact of risk factors for recurrence after the first ischemic stroke in
416 adults: A systematic review and meta-analysis. *Journal of Clinical Neuroscience*.
417 2019;60:24–30.

- 418 31. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD, South London
419 Stroke Register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and
420 outcomes of stroke recurrence in the south london stroke register. *Stroke*.
421 2003;34:1457–1463.
- 422 32. Hier DB, Foulkes MA, Swiontoniowski M, Sacco RL, Gorelick PB, Mohr JP, Price
423 TR, Wolf PA. Stroke recurrence within 2 years after ischemic infarction. *Stroke*.
424 1991;22:155–161.
- 425 33. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart-
426 Wynne EG. Long-term risk of first recurrent stroke in the perth community stroke
427 study. *Stroke*. 1998;29:2491–2500.
- 428 34. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of
429 recurrent stroke after a first-ever stroke. The Oxfordshire community stroke project.
430 *Stroke*. 1994;25:333–337.
- 431 35. Lai SM, Alter M, Friday G, Sobel E. A multifactorial analysis of risk factors for
432 recurrence of ischemic stroke. *Stroke*. 1994;25:958–962.
- 433 36. Hillen T, Dundas R, Lawrence E, Stewart JA, Rudd AG, Wolfe CD. Antithrombotic
434 and antihypertensive management 3 months after ischemic stroke: A prospective study
435 in an inner city population. *Stroke*. 2000;31:469–475.
- 436 37. Weimar C, Kraywinkel K, Hagemeister C, Haass A, Katsarava Z, Brunner F,
437 Haverkamp C, Schmid E, Diener HC, German Stroke Study Collaboration. Recurrent
438 stroke after cervical artery dissection. *Journal of Neurology, Neurosurgery, and*
439 *Psychiatry*. 2010;81:869–873.
- 440 38. Chiu D, Shedden P, Bratina P, Grotta JC. Clinical features of Moyamoya disease in
441 the united states. *Stroke*. 1998;29:1347–1351.
- 442 39. Melkas S, Sibolt G, Oksala NK, Putaala J, Pohjasvaara T, Kaste M, Karhunen PJ,

443 Erkinjuntti T. Extensive white matter changes predict stroke recurrence up to 5 years
444 after a first-ever ischemic stroke. *Cerebrovascular Diseases*. 2012;34:191–198.
445

446 **Table 1. Clinical characteristics according to stroke recurrence**

<i>Variables</i>	Recurrent stroke (n = 255)	First-ever stroke (n = 3,391)	<i>P</i> value
<i>demographics</i>			
age, yrs			0.952
<60	86 (33.7%)	1,167 (34.4%)	>0.999*
61–74	91 (35.7%)	1,178 (34.7%)	>0.999*
≥75	78 (30.6%)	1,046 (30.8%)	>0.999*
sex, male	182 (71.4%)	2,049 (60.4%)	0.001
body mass index (kg/m ²)			0.002
normal (<18.5)	90 (35.4%)	1,125 (33.3%)	>0.999*
underweight (18.5–22.9)	23 (9.1%)	147 (4.4%)	0.005*
overweight (23.0–24.9)	61 (24.0%)	784 (23.2%)	>0.999*
obese (25.0–29.9)	80 (31.5%)	1,321 (39.1%)	0.129*
current smoking	60 (23.5%)	899 (26.5%)	0.338*
<i>stroke risk factors</i>			
hypertension	176 (69.0%)	2,076 (61.2%)	0.013
diabetes mellitus	123 (48.2%)	1,120 (33.0%)	<0.001
congestive heart failure	15 (5.9%)	107 (3.2%)	0.028
atrial fibrillation	51 (20.0%)	577 (17.0%)	0.229
dyslipidemia	118 (59.6%)	2,102 (63.3%)	0.290
<i>TOAST</i>			0.003
LAD	50 (19.6%)	621 (18.3%)	>0.999*
CE	45 (17.6%)	569 (16.8%)	>0.999*
SVO	38 (14.9%)	840 (24.8%)	0.005*
OD	21 (8.2%)	183 (5.4%)	0.686*
UD	52 (20.4%)	702 (20.7%)	>0.999*
TIA	49 (19.2%)	476 (14.0%)	0.277*
<i>laboratory, radiological findings</i>			
anemia	133 (53.0%)	704 (20.8%)	<0.001
leukocytosis	34 (13.5%)	341 (10.1%)	0.085
elevated CRP	35 (18.6%)	379 (12.2%)	0.012
Hyperhomocysteinemia	32 (21.1%)	625 (20.0%)	0.756
low eGFR	65 (25.7%)	538 (15.9%)	<0.001
white matter changes	52 (20.4%)	425 (12.5%)	0.001

cerebral microbleeds	61 (23.9%)	548 (16.2%)	0.002
<i>clinical finding</i>			
poor initial NIHSS	73 (30.3%)	1,046 (31.8%)	0.667

447 Data are expressed as actual counts (percentages) unless otherwise specified.

448 As a few variables were missing, the number of available data points was 3631 for BMI, 3518 for
449 dyslipidemia, 3635 for anemia, 3635 for leukocytosis, 3307 for CRP, 3282 for homocysteine, 3639 for
450 eGFR, and 3530 for poor initial NIHSS.

451 P values without asterisks (*) were calculated from the two-way chi-square test between patients
452 with recurrent strokes and those with first-ever strokes. P values with asterisks (*) are calculated from
453 a pairwise z-test with a Bonferroni correction to account for multiple testing and were used to
454 determine the significance of the contribution for each subgroup of variables.

455 TOAST, Trial of Org. 10172 in Acute Stroke Treatment; LAD, large artery disease; CE,
456 cardioembolism; SVO, small vessel occlusion; OD, stroke of other determined etiology; UD, stroke of
457 undetermined etiology; TIA, transient ischemia attack; anemia, hemoglobin <12 g/dL in females and
458 <13 g/dL in males; leukocytosis, white blood cell count >12,000/ μ L; elevated CRP, C-reactive protein
459 ≥ 2 mg/dl; hyperhomocysteinemia, homocysteine ≥ 15 micromol/L; low eGFR, estimated glomerular
460 filtration rate <60 mL/min/1.73 m²; NIHSS, National Institutes of Health Stroke Scale

461

462

463

464

465

466

467

468

469

470

471 **Figure Legends**

472 **Figure 1.** Flowchart of patient inclusion and exclusion criteria

473 **Figure 2.** Major differences in clinical characteristics among early recurrent stroke, late
474 recurrent stroke, and first-ever stroke

475 Black (■) circular sector indicates early recurrent stroke, gray(■) indicates late recurrent
476 stroke, and white (□) indicates first-ever stroke.

477 These variables were selected, which had significant distribution in a bivariable analysis (P
478 value <0.2 in Table 1).

479 P values were calculated using the chi-square test with Bonferroni correction to determine
480 the significant distribution among early recurrent stroke, late recurrent stroke, and first-ever
481 stroke. P values with asterisks (*) and black solid lines indicate statistical significance. P
482 values without asterisks and gray dotted lines indicate no statistical significance.

483

484 **Figure 3.** Predictive factors for each recurrent stroke by multivariable logistic regression
485 analysis

486 Values were expressed as odds ratios (95% CI). Polygons and lines in the plot are expressed
487 as odds ratios (ORs) with a 95% CI. These odds ratios were adjusted for all covariates with a
488 P value <0.2, as observed in the univariate analysis.

489 Binary logistic regression analysis was used to analyze the variables associated with total
490 recurrent stroke. A multinomial logistic regression analysis was used to analyze the early and
491 late recurrent stroke variables.

492 Values in bold font, black squares, and black lines indicate statistical significance (P<0.05).

493 In contrast, values in normal font, gray circles, and gray lines indicate no statistical
494 significance.

495 The results were adjusted for sex, body mass index, hypertension, diabetes mellitus,

496 congestive heart failure, TOAST, anemia, leukocytosis, CRP, ≥ 2 mg/dL, white matter
497 changes, and cerebral microbleeds.

498 TOAST, Trial of Org. 10172 in Acute Stroke Treatment; LAD, large artery disease; CE,
499 cardioembolism; SVO, small vessel occlusion; OD, stroke of other determined etiology; UD,
500 stroke of undetermined etiology; TIA, transient ischemia attack; anemia, hemoglobin < 12
501 g/dL in females and < 13 g/dL in males; leukocytosis, white blood cell count $> 12,000/\mu\text{L}$;
502 elevated CRP, C-reactive protein ≥ 2 mg/dl; hyperhomocysteinemia, homocysteine ≥ 15
503 micromol/L; low eGFR, estimated glomerular filtration rate < 60 mL/min/1.73 m²; NIHSS,
504 National Institutes of Health Stroke Scale

Initial search of patients from the institutional database (Korea University Stroke Registry)

Inclusion criteria

- Patients with ischemic stroke or transient ischemic attacks who visited Korea University Hospitals between March 2014 and December 2021 (n = 4,508)


Exclusion criteria
(n=862)

- Refusal or omission of tests to determine stroke etiology (n = 709)
- Loss of follow-up to determine stroke recurrence or others (n = 153)


Finally, 3646 patients met the study entry criteria

Recurrent stroke
(n=255)


First-ever stroke
(n=3,391)




(1) Sex, male




(2) Body mass index




(3) Hypertension




(4) Diabetes mellitus




(5) Congestive heart failure




(6) TOAST classification




(7) Anemia




(8) Leukocytosis




(9) C-reactive protein, $\geq 2\text{mg/dL}$




(10) eGFR, $< 60 \text{ mL/min/1.73m}^2$



(11) White matter changes



(12) Cerebral microbleeds



medRxiv preprint doi: <https://doi.org/10.1101/2023.12.14.23299993>; this version posted December 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.